Arrowhead Pharmaceuticals (ARWR – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Michael Ulz from Morgan Stanley maintained a Hold rating on the stock and has a $29.00 price target.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Michael Ulz has given his Hold rating due to a combination of factors including Arrowhead Pharmaceuticals’ ongoing progress and future prospects. The company is preparing for its first product launch later this year, focusing on plozasiran for treating familial chylomicronemia syndrome (FCS), with the FDA review proceeding as anticipated and no advisory committee meeting expected. Additionally, Arrowhead is advancing its Phase 3 trials for severe hypertriglyceridemia (sHTG), with enrollment expected to complete soon and data forthcoming.
Despite these positive developments, the Hold rating reflects a cautious stance, likely due to the inherent uncertainties in drug development and regulatory approvals. While the company’s financial position appears stable with a cash runway into 2028, the success of upcoming clinical trials and market acceptance of new products remain critical factors for future growth. Investors are advised to consider these elements along with other market conditions when evaluating Arrowhead’s stock.
In another report released yesterday, Citi also maintained a Hold rating on the stock with a $17.00 price target.
Based on the recent corporate insider activity of 30 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ARWR in relation to earlier this year.